Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 15/20 | 0.70 |
| ▸ | KCNQ2 | O43526 | 15/20 | 0.70 |
| ▸ | KCNE1 | P15382 | 12/20 | 0.70 |
| ▸ | KCNQ1 | P51787 | 12/20 | 0.70 |
| ▸ | BACE1 | P56817 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215207 | 0.92 | KCNQ3 (0.81) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5649558 | 0.84 | KCNQ3 (0.74) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL2801974 | 0.83 | KCNQ3 (0.85) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5217440 | 0.83 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL1986996 | 0.83 | KCNQ3 (0.82) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL14516647 | 0.83 | RAB9A (0.72) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5214418 | 0.81 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL3313800 | 0.81 | RAB9A (0.75) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5217560 | 0.81 | KCNQ3 (0.79) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL20284429 | 0.81 | KCNQ3 (0.68) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279470-B2 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2007-10-09 | — | — | US | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| US-7067517-B2 | Use of compounds for decreasing activity of hormone-sensitive lipase | NERO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | KCNQ3 4724/4885KCNQ2 4759/4885KCNE1 4754/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | KCNQ3 4500/4885KCNQ2 4591/4885KCNE1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.